Showing results (71-80 of 99) with videos related to
Sort By:
Pageof 10
Biorxiv : the Preprint Server for Biology|August 2, 2024
TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancersManjari Kundu, Yoshimi E Greer, Alexei Lobanov, et al.Molecular Pharmaceutics|March 2, 2017
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsJohn S Schardt, Jinan M Oubaid, Sonya C Williams, et al.Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.Cancer Letters|April 5, 2025
TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cellsManjari Kundu, Yoshimi E Greer, Alexei Lobanov, et al.Frontiers in Oncology|March 22, 2021
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast CancerMargaret E Gatti-Mays, Sofia R Gameiro, Yohei Ozawa, et al.Research Square|November 19, 2025
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerJung-Min Lee, Junya Tabata, Tzu-Ting Huang, et al.Frontiers in Pharmacology|April 17, 2023
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancerEmily M J Fennell, Lucas J Aponte-Collazo, Wimal Pathmasiri, et al.Journal for Immunotherapy of Cancer|July 27, 2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analysesAlexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, et al.Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.Pageof 10